Jun 5, 2008 by Brian LawlerAllergan Lashes OutThe pharmaceutical announces a new drug that could promote eyelash growth.
Jun 4, 2008 by Brian LawlerErbitux's Deceptively Disappointing ResultsPoorly received lead-drug data batters ImClone shares.
Jun 2, 2008 by Brian LawlerLigand's Hail-Mary TouchdownThe drugmaker receives an unexpected advisory-panel surprise.
May 30, 2008 by Brian LawlerGilead Gets SynergisticIts newly acquired compound will play nicely with the drugmaker's existing products.
May 30, 2008 by Brian LawlerBristol-Myers' Cheap Pipeline BetThe pharmaceutical snaps up an unproven drug technology.
May 30, 2008 by Brian LawlerPDL Shakeup Lifts SharesThe interim CEO's departure is only the latest executive exit.
May 29, 2008 by Brian LawlerHuman Genome's Jam-Packed PipelineThe drugmaker has plentiful candidates heading for phase 3 testing.
May 29, 2008 by Brian LawlerIcahn Girds for Biogen BattleThe activist investor officially launches his bid to usurp Biogen's board of directors.
May 29, 2008 by Brian LawlerLigand Loses, for NowThe FDA's Magic 8 Ball says: APPROVAL UNLIKELY, TRY AGAIN LATER.
May 28, 2008 by Brian LawlerA Strange Novartis MS Drug StoryNovartis gets approval for a drug with an interesting history.
May 28, 2008 by Brian LawlerA Little-Noticed Drug RejectionThe EU temporarily blocks Sanofi and Bristol-Myers' shot at extending a drug's lifespan.
May 28, 2008 by Brian LawlerDiscovery's Costly Debt DelaySometimes a cash raise is more expensive than it could be.
May 28, 2008 by Brian LawlerNo Barrier to Deals Like ThisPrescription drugs and consumer health care often join forces.
May 28, 2008 by Brian LawlerKing Pays a Modest RansomAnother abuse-deterrent drug, cheaply purchased? Score!
May 27, 2008 by Brian LawlerPDL for Sale, Cheap!The pharmaceutical's assets are worth more than Wall Street thinks.
May 23, 2008 by Brian LawlerMyriad Making Good DealsThe pharmaceutical forges a largely excellent partnership deal for its lead drug.
May 22, 2008 by Brian LawlerEnzon Shareholders Steal the ShowA shareholder tussle overshadows clinical trial data.
May 22, 2008 by Brian LawlerNice Results for InterMune's Orphan DrugInterMune discusses study results for its lead drug candidate.
May 22, 2008 by Brian LawlerAll Is Not Lost for AstraZeneca's IressaAstraZeneca's Iressa gets a little pep back.
